Both we and other researchers reported that EGFR inhibitor Erlotinib effectively prevents LPS-induced cytokine expression in vivo, and protects mice from LPS-induced lethality suggesting a cross-talk between TLR4 and EGFR signaling pathways, which importantly affects the host prognosis following bacterial infection [10–12]. The gene discussed is EGFR; the disease is bacterial infectious disease.